ALLERGY THERAPEUTICS PLC

AGM Information • Feb 7, 2023

National Storage Mechanism | Additional information

RNS Number : 2264P

Allergy Therapeutics PLC

07 February 2023

Allergy Therapeutics plc

("Allergy Therapeutics" or the "Group")

Result of Annual General Meeting

7 February 2023 Allergy Therapeutics plc (AIM:AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, announces that all resolutions proposed at the 2022 Annual General Meeting ("AGM") held today were duly passed by shareholders on a show of hands.

Resolutions 1 to 10 (inclusive) were proposed as ordinary resolutions and resolution 11 was proposed as a special resolution. The results of the proxy votes received ahead of the meeting are outlined in the table below.

Resolution	For:	%age	Against:	%age	Total Votes Cast	% of ISC	Withheld
1. To re-elect Manual Llobet as a Director	220,438,209	99.55	438,504	0.20	220,876,713	32.52	112,037
To re-elect Cheryl MacDiarmid as a Director	220,433,972	99.55	448,778	0.20	220,882,750	32.53	106,000
3. To re-elect Anthony Parker as a Director	218,552,445	98.70	2,324,268	1.05	220,876,713	32.52	112,037
4. To re-elect Zheqing (Simon) Shen as a Director	218,556,682	98.70	2,326,068	1.05	220,882,750	32.53	106,000
5. To re-elect Mary Tavener as a Director	220,433,972	99.55	442,741	0.20	220,876,713	32.52	112,037
6. To re-elect Tunde Otulana as a Director	220,433,972	99.55	442,741	0.20	220,876,713	32.43	112,037
7. To re-elect Peter Jensen as a Director	217,599,392	98.55	2,641,372	1.20	220,240,764	32.43	747,986
8. To re-appoint BDO LLP as auditors of the Company	218,640,401	99.63	235,796	0.11	218,876,197	32.23	2,112,553
9. To authorise the Directors to agree the Auditors remuneration	217,956,401	99.31	938,759	0.43	218,895,160	32.23	2,093,590
10. To authorise the Directors to allot the unissued share capital up to a specific amount (s.551)	220,517,191	99.58	366,559	0.17	220,883,750	32.53	105,000
11. Special Resolution: To adopt the Articles of Association	220,515,891	99.60	336,822	0.15	220,852,713	32.52	136,037

- ENDS -

For further information, please contact:

Allergy Therapeutics

+44 (0)1903 845 820

Manuel Llobet, Chief Executive Officer

Martin Hopcroft, Interim Chief Financial Officer

Panmure Gordon (Nominated Adviser and Broker)

+44 (0)20 7886 2500

Freddy Crossley, Emma Earl, Corporate Finance

Rupert Dearden, Corporate Broking

Consilium Strategic Communications

+44 (0)20 3709 5700

Mary-Jane Elliott / David Daley / Davide Salvi

allergytherapeutics@consilium-comms.com

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company, headquartered in the UK, focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development includes vaccines for grass, tree, house dust mite and peanut. For more information, please see www.allergytherapeutics.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGSSAFAWEDSEEE